Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Erlotinib in Stage IIIA N2-positive NSCLC
NCT01130753Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Jan 2007
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Started Jan 2007; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01130753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01130753.